Carlos L. Arteaga, M.D., was appointed Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center in September 2017. He holds the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology and brings translational research and cancer center leadership experience to the Simmons Cancer Center.
He earned his medical degree at the University of Guayaquil in Ecuador and trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center San Antonio, respectively. He joined Vanderbilt University in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served as Director of the Center for Cancer Targeted Therapies, Director of the Breast Cancer Program, and Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center prior to UT Southwestern.
Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been continuously funded by the National Cancer Institute, American Cancer Society (ACS), Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), Susan G. Komen and Breast Cancer Research foundations, Cancer Prevention Research Institute of Texas, and industry.
His contributions have been published in Nature Medicine, Cancer Cell, Cancer Discovery, Science Translational Medicine, Journal of Clinical Oncology, Cell Metabolism, Journal of Clinical Investigation, Proceeding of the National Academy of Sciences of the United States of American, and Journal of the National Cancer Institute.
During his career, he has received several awards, including the American Association for Cancer Research (AACR) Richard & Hinda Rosenthal Award, the ACS Clinical Research Professor Award (2007-2017), the Gianni Bonadonna Award from the American Society of Clinical Oncology (2009), the Brinker Award from the Susan G. Komen Foundation (2011), the Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation (2015), and the Clinical Investigator Award from the Department of Veteran Affairs.
Dr. Arteaga is a Fellow of the American Association for the Advancement of Science (2013) and Fellow of the AACR Academy (2015). He is an elected member of the American Society for Clinical Investigation (1998) and the Association of American Physicians (2005). He served on the NCI Board of Scientific Counselors (1999-2004) and NCI Subcommittee A (2004-2008).
Dr. Arteaga also serves on the advisory boards of several academic breast cancer programs, SU2C, Susan G. Komen Foundation, and five NCI-designated cancer centers. Since 2009, he has co-chaired the San Antonio Breast Cancer Symposium. In 2019, he was elected to serve on the Board of Directors of the American Association of Cancer Institutes (AACI). He was elected and served as the 2014-15 President of AACR, the largest cancer research organization in the world.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- Is There a Future for AKT Inhibitors in the Treatment of Cancer?
- Jansen VM, Mayer IA, Arteaga CL Clin. Cancer Res. 2016 Jun 22 11 2599-601
- Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
- Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL Sci Transl Med 2016 Apr 8 334 334ra53
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
- Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM Clin. Cancer Res. 2016 Mar 22 6 1499-509
- Systematic Prioritization of Druggable Mutations in ~5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
- Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao Z Mol. Cell Proteomics 2016 Feb 15 2 642-56
- Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
- Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL Cancer Res. 2016 Jan 76 2 440-52
- Drug response in organoids generated from frozen primary tumor tissues.
- Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC Sci Rep 2016 Jan 6 18889
- The PI3K/AKT Pathway as a Target for Cancer Treatment.
- Mayer IA, Arteaga CL Annu. Rev. Med. 2016 67 11-28
- Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
- Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ Circulation 2015 Dec 132 23 2248-58
- Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
- Young CD, Arteaga CL, Cook RS Breast Cancer Res. 2015 Dec 17 148
- HER2 missense mutations have distinct effects on oncogenic signaling and migration.
- Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH Proc. Natl. Acad. Sci. U.S.A. 2015 Nov 112 45 E6205-14